Evidence map›Paper›PMID 32843683›Full record

ArticleBritish journal of cancer2020

Bowel inflammation in cancer patients: the microbiome, antibiotics and interleukin-9.

Niels Halama

Open access · hybridAbstract readEditorialComment
In one paragraph

Article in British journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Niels HalamaDepartment of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany. niels.halama@nct-heidelberg.de.ORCID http://orcid.org/0000-0003-0344-6027
German Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microbiome composition can impact disease courses and also immunotherapy outcomes in solid tumours. It is still unclear how the microbiome might impact treatments in oncology, but also how modulation via antibiotics might interfere. Elegant work now identified interleukin-9 and dysbiosis as relevant factors, providing some answers for these questions.

Indexed as

Gastrointestinal MicrobiomeMicrobiotaNeoplasmsAnti-Bacterial AgentsCell DifferentiationDysbiosisHumansInflammationInterleukin-9Anti-Bacterial AgentsInterleukin-9

Identifiers

PMID32843683
PMCPMC7652919
OpenAlexW3080503084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.